JPH0452117B2 - - Google Patents
Info
- Publication number
- JPH0452117B2 JPH0452117B2 JP59041436A JP4143684A JPH0452117B2 JP H0452117 B2 JPH0452117 B2 JP H0452117B2 JP 59041436 A JP59041436 A JP 59041436A JP 4143684 A JP4143684 A JP 4143684A JP H0452117 B2 JPH0452117 B2 JP H0452117B2
- Authority
- JP
- Japan
- Prior art keywords
- nad
- activity
- buffer
- enzyme
- ldh
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000000694 effects Effects 0.000 claims description 21
- 239000003112 inhibitor Substances 0.000 claims description 17
- 102000004190 Enzymes Human genes 0.000 claims description 13
- 108090000790 Enzymes Proteins 0.000 claims description 13
- 239000000872 buffer Substances 0.000 claims description 8
- 230000001419 dependent effect Effects 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 238000006911 enzymatic reaction Methods 0.000 claims description 4
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 48
- 229950006238 nadide Drugs 0.000 description 47
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 12
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 12
- 238000000034 method Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 101000950981 Bacillus subtilis (strain 168) Catabolic NAD-specific glutamate dehydrogenase RocG Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 102000016901 Glutamate dehydrogenase Human genes 0.000 description 2
- 108010009384 L-Iditol 2-Dehydrogenase Proteins 0.000 description 2
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 2
- 108010026217 Malate Dehydrogenase Proteins 0.000 description 2
- 102000013460 Malate Dehydrogenase Human genes 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102100026974 Sorbitol dehydrogenase Human genes 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010008488 Glycylglycine Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000003028 enzyme activity measurement method Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940043257 glycylglycine Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 239000005373 porous glass Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- HHLJUSLZGFYWKW-UHFFFAOYSA-N triethanolamine hydrochloride Chemical compound Cl.OCCN(CCO)CCO HHLJUSLZGFYWKW-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Description
本発明は高活性のニコチンアミドアデニンジヌ
クレオタイド(NAD+という)の製造法に関する
ものである。
更に詳細には、NAD+中に混在するNAD+活性
阻害物質を除去することによつて高活性のNAD+
を製造する方法に関するものである。
一般に、NAD+は生化学研究や臨床検査の分野
で今日最も広く使用されている助酵素であつて、
純度が高く、高活性のものが望まれるものであ
る。
しかしながら、NAD+の標品においてもしばし
ば活性の低下がみられるものである。
活性の低下したNAD+標品について詳細に検討
すると、NAD+活性を阻害する物質が認められる
のである。NAD+活性阻害物質について検検討し
ようとしても、分離精製がきわめて困難なため現
在阻害物質の構造並びに性質については全く不明
な状態である。
しかし、NAD+標品にNAD+活性阻害物質が含
まれると、NAD+標品を使用する酵素活性測定の
精度や酵素反応解析に大きな影響を与えるため
に、NAD+活性阻害物質は必ず除去しなければな
らないのである。NAD+活性阻害物質の物性その
ものが不明であるために、該物質の分離法の手が
かりすらつかめていないのが現状である。
本発明者らは、NAD+標品NAD+活性阻害物質
を除去するために鋭意研究したところ、NAD+活
性阻害物質はNAD+依存性酵素に吸着され、
NAD+から分離されることを知つたのである。
本発明は、酵素反応を行うことなく、NAD+活
性阻害物質を含有するNAD+とNAD+依存性酵素
の一種もしくは二種以上とを緩衝中で接触させ
て、NAD+に含有されるNAD+活性阻害物質を除
去し、NAD+を回収することを特徴とする高活性
NAD+の製造法である。
本発明において、NAD+依存性酵素としては乳
酸脱水素酵素(LDH)、アルコール脱水酵素
(ADH)、リンゴ酸脱水素酵素(MDH)、ソルビ
トール脱水素酵素(SDH)、グルタミン酸脱水素
酵素(GlDH)などがあげられるが、LDHが最
も好ましい。
本発明においては、NAD+活性阻害物質を含有
するNAD+標品を適当な緩衝液中でLDHなどと
共存させると、阻害物質は急速にLDHなどに吸
着され、NAD+を回収することによつて容易に阻
害物質を全く含有しないNAD+を調製することが
できる。ここで用いる緩衝液の種類としては、通
常酵素反応に使用される緩衝液であればいずれで
もよい。具体的には、リン酸、トリース塩酸、ト
リエタノールアミン−塩酸、ヒスチジン−塩酸、
グリシルグリシン、グツド緩衝液などがある。緩
衝液の濃度は10mMから550mMいずれでもよく、
好ましくは50mMから208mMである。また緩衝
液のPHは5.5から9.0でよく、好ましくは6.0から
7.5である。
また、NAD+依存性酵素としてはいずれの種類
でも、いずれの給源のものでもよい。LDHの給
源としてはうさぎ筋肉、ブタ心臓、ブタ筋肉、牛
心臓、牛筋肉などの動物給源やロイコノストツ
ク、メセンテロイデス、高温菌などの細菌給源あ
るいは植物給源などがあるが、いずれの給源から
のLDHも使用できる。また使用する酵素は溶液
状態あるいは固定化状態いずれの形態でもよい
が、NAD+標品の回収には固定化状態のほうがよ
り好ましい。
酵素の固定化法には共有結合法、イオン結合
法、物理的吸着法、架橋法、包括法などがあり、
一方、固定化担体としては、セルロース、アガロ
ース、デキストランなどの多糖類、多孔性ガラ
ス、ポリアクリルアミド、カラギーナン、ポリウ
レタンなどがあるがいずれの方法および担体でも
よい。
NAD+とNAD+依存性酵素は緩衝液中で接触さ
せられるが、その接触反応温度は2℃から40℃い
ずれでもよく、好ましくは2℃から10℃である。
この処理によつてNAD+活性阻害物質は酵素に
吸着されるので、酵素を分離すれば高活性の
NAD+を得ることができる。
酵素が固定化されている場合は、これをカラム
につめ、NAD+標品を含有する緩衝液を流下し、
途中でNAD+活性阻害物質を酵素に吸着させて高
活性のNAD+を直接得ることができる。
次に本発明の実施例を示す。
実施例 1
100mMリン酸緩衝液(PH6.5)にNAD+粉末約
100mgを溶解し4NKOHでPHを6.0に調整した後、
そこへ約10000単位のLDHを入れ、10℃で10分間
反応させた。
反応液を限外過し、液を集め、LDHの除
去されたNAD+を回収する。回収したNAD+溶液
についての分析結果を表1に示した。
尚、NAD+中の阻害物質の含有程度はつぎの様
にして測定される。
0.1MTris−HCl(PH8.5)0.90ml、80mM
NAD+溶液(PH8.5)約8u/mlウサギ筋肉LDHを
キユーベツトに入れ、25℃5分間インキユベーシ
ヨンを行う。その後40mM L−乳酸を1.2mlを加
え、分光光度計を用い25℃での1分間当りの吸光
度変化を測定する。
阻害物質を含有していないと思われる標準
NAD+でのΔA0/minとNAD+サンプルでの
ΔA/minとの比を求め、阻害物質の含有程度を
相対活性として表わす(ΔA/min/ΔA0/min×100)。
The present invention relates to a method for producing highly active nicotinamide adenine dinucleotide (NAD + ). More specifically, by removing NAD + activity inhibitors mixed in NAD + , highly active NAD +
The present invention relates to a method for manufacturing. In general, NAD + is the coenzyme most widely used today in the fields of biochemical research and clinical testing.
High purity and high activity are desired. However, even in NAD + preparations, a decrease in activity is often observed. A detailed study of NAD + preparations with reduced activity reveals substances that inhibit NAD + activity. Even if we try to examine NAD + activity inhibitors, the structure and properties of the inhibitors are currently completely unknown because separation and purification is extremely difficult. However, if NAD + activity inhibitors are contained in NAD + preparations, they will have a major impact on the accuracy of enzyme activity measurements and enzyme reaction analysis using NAD + preparations, so NAD + activity inhibitors must be removed. It has to be. Since the physical properties of the NAD + activity inhibitor are unknown, at present we have no clue how to isolate the substance. The present inventors conducted intensive research to remove the NAD + standard NAD + activity inhibitor, and found that the NAD + activity inhibitor was adsorbed to NAD + dependent enzymes.
They learned that it can be separated from NAD + . The present invention involves contacting NAD + containing an NAD + activity inhibitor with one or more types of NAD + dependent enzymes in a buffer without performing an enzymatic reaction. High activity characterized by removing activity inhibitors and recovering NAD +
This is a method for producing NAD + . In the present invention, NAD + dependent enzymes include lactate dehydrogenase (LDH), alcohol dehydrase (ADH), malate dehydrogenase (MDH), sorbitol dehydrogenase (SDH), and glutamate dehydrogenase (GlDH). etc., but LDH is the most preferred. In the present invention, when an NAD + preparation containing an NAD + activity inhibitor is allowed to coexist with LDH etc. in an appropriate buffer, the inhibitor is rapidly adsorbed to LDH etc., and NAD + is recovered. Therefore, NAD + can be easily prepared that does not contain any inhibitory substances. The type of buffer used here may be any buffer as long as it is normally used in enzyme reactions. Specifically, phosphoric acid, Tries hydrochloric acid, triethanolamine-hydrochloric acid, histidine-hydrochloric acid,
Examples include glycylglycine and Gutud buffer. The concentration of the buffer solution may be anywhere from 10mM to 550mM,
Preferably it is 50mM to 208mM. In addition, the pH of the buffer solution may be between 5.5 and 9.0, preferably between 6.0 and 9.0.
It is 7.5. Further, the NAD + -dependent enzyme may be of any type and from any source. Sources of LDH include animal sources such as rabbit muscle, pig heart, pig muscle, cow heart, and bovine muscle, bacterial sources such as Leuconostoccus, Mesenteroides, and thermophilic bacteria, and plant sources, but LDH from any source can be used. can. Further, the enzyme used may be in either a solution state or an immobilized state, but the immobilized state is more preferable for recovering the NAD + specimen. Enzyme immobilization methods include covalent bonding, ionic bonding, physical adsorption, crosslinking, and inclusion methods.
On the other hand, immobilization carriers include cellulose, agarose, polysaccharides such as dextran, porous glass, polyacrylamide, carrageenan, polyurethane, etc., and any method and carrier may be used. NAD + and the NAD + -dependent enzyme are brought into contact in a buffer solution, and the contact reaction temperature may be anywhere from 2°C to 40°C, preferably from 2°C to 10°C. Through this treatment, NAD + activity inhibitors are adsorbed to the enzyme, so if the enzyme is separated, highly active substances can be obtained.
You can get NAD + . If the enzyme is immobilized, it is packed in a column, and a buffer containing the NAD + preparation is flowed down.
During the process, highly active NAD + can be directly obtained by adsorbing NAD + activity inhibitors onto the enzyme. Next, examples of the present invention will be shown. Example 1 NAD + powder in 100mM phosphate buffer (PH6.5) approx.
After dissolving 100mg and adjusting the pH to 6.0 with 4NKOH,
Approximately 10,000 units of LDH was added thereto and reacted at 10°C for 10 minutes. The reaction solution is subjected to ultrafiltration, the solution is collected, and NAD + from which LDH has been removed is recovered. Table 1 shows the analysis results for the recovered NAD + solution. Incidentally, the content level of the inhibitory substance in NAD + is measured as follows. 0.1MTris-HCl (PH8.5) 0.90ml, 80mM
Place about 8 u/ml rabbit muscle LDH in NAD + solution (PH8.5) in a cuvette and incubate at 25°C for 5 minutes. Thereafter, 1.2 ml of 40 mM L-lactic acid was added, and the change in absorbance per minute at 25°C was measured using a spectrophotometer. Standards that do not appear to contain inhibitors
The ratio between ΔA 0 /min for NAD + and ΔA /min for NAD + sample is determined, and the degree of inhibitory substance content is expressed as relative activity (ΔA/min/ΔA 0 /min×100).
【表】
実施例 2
ブロムシアン法でセフアロース30mlにLDH300
mg固定したLDHゲル3mlをつめたカラムに
0.1MK−PO4(PH7.0)を流しカラムを平衡化させ
る。ついで100mg/mlNAD+溶液(PH7.0)1mlカ
ラムへ流し、その後同じ緩衝液でNAD+を溶出し
た。
カラムから回収されたNAD+について、実施例
1と同様に分析を行つた。分析結果を表1に示し
た。[Table] Example 2 Add 300 LDH to 30 ml of Cepharose using Bromsian method
Into a column filled with 3 ml of LDH gel fixed in mg.
Flow 0.1MK-PO 4 (PH7.0) to equilibrate the column. A 100 mg/ml NAD + solution (PH7.0) was then applied to a 1 ml column, and then NAD + was eluted with the same buffer. NAD + recovered from the column was analyzed in the same manner as in Example 1. The analysis results are shown in Table 1.
Claims (1)
質を含有するNAD+とNAD+依存性酵素の一種も
しくは二種以上とを緩衝液中で接触させて、
NAD+に含有されるNAD+活性阻害物質を除去
し、NAD+を回収することを特徴とする高活性
NAD+の製造法。 2 NAD+依存性酵素が固定化されたものである
ことを特徴とする特許請求の範囲第1項記載の高
活性NAD+の製造法。[Claims] 1. Bringing NAD + containing an NAD + activity inhibitor into contact with one or more NAD + dependent enzymes in a buffer without performing an enzymatic reaction,
High activity characterized by removing NAD + activity inhibitors contained in NAD + and recovering NAD +
Method of manufacturing NAD + . 2. The method for producing highly active NAD + according to claim 1, wherein the NAD + dependent enzyme is immobilized.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4143684A JPS60186297A (en) | 1984-03-06 | 1984-03-06 | Removal of nad+ activation inhibitor |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4143684A JPS60186297A (en) | 1984-03-06 | 1984-03-06 | Removal of nad+ activation inhibitor |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS60186297A JPS60186297A (en) | 1985-09-21 |
JPH0452117B2 true JPH0452117B2 (en) | 1992-08-20 |
Family
ID=12608318
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP4143684A Granted JPS60186297A (en) | 1984-03-06 | 1984-03-06 | Removal of nad+ activation inhibitor |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS60186297A (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5554894A (en) * | 1978-10-13 | 1980-04-22 | Toyobo Co Ltd | Novel formaldehyde-dehydrogenase and its preparation |
JPS5816873A (en) * | 1981-07-23 | 1983-01-31 | Usac Electronics Ind Co Ltd | Regulation of stopping position of printing medium |
-
1984
- 1984-03-06 JP JP4143684A patent/JPS60186297A/en active Granted
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5554894A (en) * | 1978-10-13 | 1980-04-22 | Toyobo Co Ltd | Novel formaldehyde-dehydrogenase and its preparation |
JPS5816873A (en) * | 1981-07-23 | 1983-01-31 | Usac Electronics Ind Co Ltd | Regulation of stopping position of printing medium |
Also Published As
Publication number | Publication date |
---|---|
JPS60186297A (en) | 1985-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Darrow et al. | [25] Hexokinase from Baker's yeast: ATP+ Hexose→ ADP+ Hexose-6-phosphate+ H+ | |
PT98564B (en) | PROCESS FOR THE CONDUCT OF ENZYME CATALYZED PROCESSES WITH CRYSTALS RETICULATED AS A FORM OF FIXING ENZYMES AND DEVICES THAT CONTAIN THEM | |
Inman et al. | Preparation of some immobilized linked enzyme systems and their use in the automated determination of disaccharides | |
EP0105736B1 (en) | Immobilization of proteins on polymeric supports | |
Orth et al. | Carrier‐Bound Biologically Active Substances and Their Applications | |
Jurtshuk et al. | Isolation and purification of the D (–) β-hydroxybutyric dehydrogenase of Azotobacter vinelandii | |
JPH0440987B2 (en) | ||
JPH0452117B2 (en) | ||
US4087328A (en) | Purification and immobilization of sulfhydryl oxidase | |
US3951744A (en) | Purification of dehydrogenases | |
JP3143050B2 (en) | Stabilized glucose 6-phosphate dehydrogenase | |
JPH0466875B2 (en) | ||
US4194067A (en) | Process for the purification of carbohydrate containing enzymes | |
US4042461A (en) | Method for purifying cholesterol esterase | |
Klibanov et al. | Thermal stabilities of membrane-bound, solubilized, and artificially immobilized hydrogenase from Chromatium vinosum | |
US3810823A (en) | Method for isolation of enzymes | |
KR950014967B1 (en) | Preparation method of moranoline derivatives | |
JPS5974996A (en) | Method for measuring humoral component of living body | |
RU2054481C1 (en) | Method of immobilized enzyme preparing | |
MISTUDA et al. | On the enzymatic hydrolysis of FAD in spinach leaves | |
Moskvitina et al. | On preparative separation of brain mitochondrial monoamine oxidases | |
JPS6120268B2 (en) | ||
Rashid et al. | A dual-enzyme electrode for the determination of flavin adenine dinucleotide in the presence of riboflavin and flavin mononucleotide | |
Horowitz et al. | Generalized affinity chromatography: enzyme-sulfonamide conjugates can be isolated by adsorption on immobilized carbonic anhydrase | |
JP2748416B2 (en) | Manufacturing method of bioactive substance-immobilized membrane |